ArticleMolecular pharmaceutics
In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines.
Article in Molecular pharmaceutics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 77 citations in OpenAlex.
- Vinyl Sulfone-functionalized Acetalated Dextran Microparticles as a Subunit Broadly Acting Influenza Vaccine.The AAPS journal · 2023Article
- Spatio-temporal delivery of both intra- and extracellular toll-like receptor agonists for enhancing antigen-specific immune responses.Acta pharmaceutica Sinica. B · 2022Article
- Programmable multistage drug delivery to lymph nodes.Nature nanotechnology · 2020Article
- Comparative Study of 5'- and 3'-Linked CpG-Antigen Conjugates for the Induction of Cellular Immune Responses.ACS omega · 2017Article
- Intracellular Cleavable CpG Oligodeoxynucleotide-Antigen Conjugate Enhances Anti-tumor Immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Coordinating antigen cytosolic delivery and danger signaling to program potent cross-priming by micelle-based nanovaccine.Cell discovery · 2017Article
- Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy.Biomaterials · 2016Article
- Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses.Vaccine · 2016Article
- Adjuvants: Classification, Modus Operandi, and Licensing.Journal of immunology research · 2016Review
- Degradable vinyl polymers for biomedical applications.Nature chemistry · 2015Review
- Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.Vaccine · 2015Article
- The TLR4 agonist fibronectin extra domain A is cryptic, exposed by elastase-2; use in a fibrin matrix cancer vaccine.Scientific reports · 2015Article
- Tumor lysate-loaded biodegradable microparticles as cancer vaccines.Expert review of vaccines · 2014Review
- Nanocarrier-based immunotherapy in cancer management and research.ImmunoTargets and therapy · 2014Review
- Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Key roles of adjuvants in modern vaccines.Nature medicine · 2013Review
- pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides.ACS nano · 2013Article
- Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases.Journal of the Royal Society, Interface · 2013Review
- Reductively responsive siRNA-conjugated hydrogel nanoparticles for gene silencing.Journal of the American Chemical Society · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
Protein-based vaccines have been explored as a safer alternative to traditional weakened or killed whole organism based vaccination strategies and have been investigated for their ability to activate the immune system against certain cancers. For optimal stimulation of T lymphocytes, protein-based vaccines should deliver protein antigens to antigen presenting cells in the context of appropriate immunostimulatory signals, thus mimicking actual pathogens. In this report, we describe the synthesis, characterization, and biological evaluation of immunostimulatory acid-degradable microparticles, which are suitable delivery vehicles for use in protein-based vaccines and cancer immunotherapy. Using a 3' conjugation strategy, we optimized the attachment of immunostimulatory CpG DNA to our vaccine carriers and demonstrated that under acidic conditions similar to those found in endosomal compartments, these new particles were capable of simultaneously releasing a model protein antigen and a CpG DNA adjuvant. We found in an in vivo cytotoxicity assay that the co-encapsulation of ovalbumin, a model antigen, and immunostimulatory agent in the same particle led to superior cytotoxic T lymphocyte activity compared to particles coadministered with adjuvant in an unbound form. In addition, we investigated the ability of these acid-degradable particles to induce protective immunity in the MO5 murine melanoma model and found that they were effective until tumor escape, which appeared to result from a loss of antigen expression by the cancer cells due to in vivo selection pressure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.